LifeVantage Corp (NASDAQ:LFVN) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 786,800 shares, an increase of 83.1% from the June 15th total of 429,600 shares. Based on an average daily volume of 128,400 shares, the short-interest ratio is currently 6.1 days. Approximately 6.0% of the shares of the company are short sold.
Institutional investors have recently bought and sold shares of the company. Raymond James & Associates bought a new position in shares of LifeVantage in the fourth quarter valued at approximately $174,000. Two Sigma Advisers LP boosted its holdings in shares of LifeVantage by 35.9% in the fourth quarter. Two Sigma Advisers LP now owns 14,372 shares of the company’s stock valued at $190,000 after acquiring an additional 3,800 shares in the last quarter. First Trust Advisors LP boosted its holdings in shares of LifeVantage by 18.7% in the fourth quarter. First Trust Advisors LP now owns 23,106 shares of the company’s stock valued at $305,000 after acquiring an additional 3,634 shares in the last quarter. Tibra Equities Europe Ltd bought a new stake in LifeVantage during the first quarter worth approximately $350,000. Finally, WINTON GROUP Ltd boosted its holdings in LifeVantage by 55.6% during the second quarter. WINTON GROUP Ltd now owns 28,229 shares of the company’s stock worth $366,000 after buying an additional 10,088 shares in the last quarter. Institutional investors and hedge funds own 37.38% of the company’s stock.
NASDAQ LFVN traded up $0.12 on Friday, hitting $11.31. The stock had a trading volume of 59,041 shares, compared to its average volume of 130,351. LifeVantage has a one year low of $8.44 and a one year high of $17.08. The stock has a market cap of $161.55 million, a PE ratio of 22.18 and a beta of 0.70. The firm’s 50-day simple moving average is $11.91.
LifeVantage (NASDAQ:LFVN) last posted its earnings results on Wednesday, May 1st. The company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.14 by ($0.01). The firm had revenue of $56.01 million during the quarter. LifeVantage had a return on equity of 33.86% and a net margin of 2.91%. On average, sell-side analysts forecast that LifeVantage will post 0.52 EPS for the current fiscal year.
LifeVantage Corporation engages in the identification, research, development, and distribution of nutraceutical dietary supplements and skin care products. The company offers Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skin care product; Axio, a line of energy drink mixes; Omega+, a fish oil dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and Vitamin D3; and PhysIQ, a weight management system, as well as Petandim for Dogs, a companion pet supplement formulated to treat oxidative stress in dogs.
Recommended Story: Understanding Average Daily Trade Volume
Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.